Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,109

Ambassador Nancy G. Brinker (https://nancybrinker.com/) is Founder of the Susan G. Komen Breast Cancer Foundation (https://www.komen.org/) and Co-Founder of the Promise Fund of Florida (https://www.promisefundofflorida.org/).

Amb. Brinker is a three-time Ambassador and New York Times best-selling author who is regarded as the leader of the global breast cancer movement. Her journey began with a promise to her dying sister, Susan G. Komen, that she would do everything possible to end the shame, pain, fear, and hopelessness caused by this disease. In one generation, the organization that bears Susan’s name has changed the world.

In 2009, President Barack Obama honored Amb. Brinker with the Presidential Medal of Freedom, the nation’s highest civilian honor, for this work. The same year, she was named Goodwill Ambassador for Cancer Control for the United Nations’ World Health Organization, where she continued her mission to put cancer control at the top of the world health agenda.

In 2010, Amb. Brinker released her New York Times best-selling memoir “Promise Me — How a Sister’s Love Launched the Global Movement to End Breast Cancer” (https://www.amazon.com/gp/product/0307718123?ie=UTF8&tag=lif…07718123), an inspirational story of her transformation from bereaved sister to the undisputed leader of the ongoing international movement to end breast cancer.

From 2001–2003, Amb. Brinker served as U.S. Ambassador to the Republic of Hungary and served as U.S. Chief of Protocol from 2007–2009.

Amb. Brinker is also the host of a weekly show on Newsmax TV which features news makers, corporate leaders, and high-profile cultural thought leaders.

Continue reading “Ambassador Nancy G. Brinker — Leading A Global Movement To End Breast Cancer” | >

Microgrids are the right solution for rural and remote energy production and distribution because they are grids designed for smaller populations.

In the United States, there are at least 60,000 people who have no access to electricity. It is not a large number but poses for this population a barrier to participating in the modern world. You cannot find a job working from home without electricity and Internet access. You cannot visit your doctor virtually. You cannot use electricity to light and heat your home.

But with microgrids that can operate autonomously from the main power grid, rural and remote communities can do everything that people living in big cities can do leading to a better quality of life for those living there.

A Toronto, Canada, based company is a microgrid solutions provider. Called Clear Blue Technologies, it offers energy-as-a-service to rural and remote communities. In Nigeria, it is installing microgrids and distributed energy solutions to help rural communities to access energy and telecommunications services. Its service model manages these installations remotely at a low cost delivering clean renewable electricity while giving rural users access to the Internet. For Nigerian remote communities, it brings them into the 21st century. That’s why in March of this year, Clear Blue was awarded a contract covering 120 telecommunications sites across the country with plans in the next five years to grow that number to 1,060. Talk about levelling the playing field for these communities to give them access to clean energy and cellular phone services.

Read more | >

A comprehensive analysis of bacterial communities from Deception Island, an active volcano in Antarctica, highlights the potential for using heat-loving bacteria to clean up oil contamination, new research led by KAUST researchers shows.

Júnia Schultz recently joined KAUST as a postdoc working with Alexandre Rosado. She has set her sights on characterizing the microbiome of extreme terrestrial environments in Saudi Arabia, including volcanoes, deserts and geothermal sites. These extremophiles, bacteria that grow in the world’s most extreme environments, including those that love heat (thermophiles), hold immense potential for a myriad of biotechnology applications.

“Extremophiles thrive under a multitude of hostile conditions and have adapted to remain metabolically active in challenging circumstances,” says Schultz. “They exhibit versatile, diverse metabolic and physiological capabilities and often synthesize valuable bioproducts.”

Read more | >

A new systematic review has presented strong evidence the development of type 1 diabetes is linked to infection by enterovirus, a large group of common viruses. The findings build on a growing hypothesis linking the viruses to type 1 diabetes, with vaccines currently in development targeting the most likely viral strains.

The suggestion an enterovirus infection can trigger type 1 diabetes goes back more than 50 years, to a report published in 1969 that linked new-onset diabetes to recent infections with an enterovirus called Coxsackie B. Since then there have been a number of different studies published digging into this link, and the results have been frustratingly inconsistent.

A key 2011 study offered the first systematic review on the subject, focusing on modern molecular testing techniques (such as PCR tests). It found a clinically significant association between enterovirus infection and type 1 diabetes.

Read more | >

When it comes to developing treatments and eventual cures for diseases, being able to diagnose a condition early and accurately makes a huge difference – and scientists have now developed a quick, reliable method of identifying people with Parkinson’s disease.

The test can be run in as little as 3 minutes after a skin swab has been taken. The swab is analyzed for changes in the chemical mix of sebum, a natural waxy oil produced by the skin that has previously been linked to Parkinson’s.

At the moment, there’s no conclusive test for Parkinson’s disease – specialists look at symptoms, medical history, the results of a lengthy physical examination, and in some cases, a brain scan to diagnose the condition.

Read more | >

Because of its distinctive and adorable look, the axolotl Ambystoma mexicanum is a popular pet. Unlike other metamorphosing salamanders, axolotls (pronounced ACK-suh-LAH-tuhl) never outgrow their larval, juvenile stage, a trait known as neoteny. It’s also recognized for its ability to regenerate missing limbs and other tissues including the brain, spinal cord, tail, skin, limbs, liver, skeletal muscle, heart, upper and lower jaw, and ocular tissues like the retina, cornea, and lens.

Mammals, including humans, are almost incapable of rebuilding damaged tissue after a brain injury. Some species, such as fish and axolotls, on the other hand, may replenish wounded brain regions with new neurons.

Read more | >

So how should companies begin to think about ethical data management? What measures can they put in place to ensure that they are using consumer, patient, HR, facilities, and other forms of data appropriately across the value chain—from collection to analytics to insights?

We began to explore these questions by speaking with about a dozen global business leaders and data ethics experts. Through these conversations, we learned about some common data management traps that leaders and organizations can fall into, despite their best intentions. These traps include thinking that data ethics does not apply to your organization, that legal and compliance have data ethics covered, and that data scientists have all the answers—to say nothing of chasing short-term ROI at all costs and looking only at the data rather than their sources.

In this article, we explore these traps and suggest some potential ways to avoid them, such as adopting new standards for data management, rethinking governance models, and collaborating across disciplines and organizations. This list of potential challenges and remedies is not exhaustive; our research base was relatively small, and leaders could face many other obstacles, beyond our discussion here, to the ethical use of data. But what’s clear from our research is that data ethics needs both more and sustained attention from all members of the C-suite, including the CEO.

Read more | >

Ground-breaking research at Tel Aviv University successfully eradicated glioblastoma, a deadly form of brain cancer. The researchers achieved the result by developing a strategy based on their finding of two crucial mechanisms in the brain that promote tumor growth and survival: one shields cancer cells from the immune system, while the other provides the energy needed for rapid tumor growth. The research discovered that astrocytes, which are brain cells, regulate both methods, and that when they aren’t there, tumor cells die and are eliminated.

Rita Perelroizen, a Ph.D. student, served as the study’s lead researcher. She collaborated with Professor Eytan Ruppin of the National Institutes of Health (NIH) in the United States and was supervised by Dr. Lior Mayo of the Shmunis School of Biomedicine and Cancer Research and the Sagol School of Neuroscience at Tel Aviv. The study was recently published in the journal Brain and was highlighted with scientific commentary.

Read more | >